A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework

Published in Cancer and Protocols & Methods
A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Neuroblastoma (NB) is one of the leading causes of cancer-associated death in children. MYCN amplification is a prominent genetic marker for NB, and its targeting to halt NB progression is difficult to achieve. Therefore, an in-depth understanding of the molecular interactome of NB is needed to improve treatment outcomes. Analysis of NB multi-omics unravels valuable insight into the interplay between MYCN transcriptional and miRNA post-transcriptional modulation. Moreover, it aids in the identification of various miRNAs that participate in NB development and progression.

This study proposes an integrated computational framework with three levels of high-throughput NB data (mRNA-seq, miRNA-seq, and methylation array). Similarity Network Fusion (SNF) and ranked SNF methods were utilized to identify essential genes and miRNAs. The specified genes included both miRNA-target genes and transcription factors (TFs). The interactions between TFs and miRNAs and between miRNAs and their target genes were retrieved where a regulatory network was developed. Finally, an interaction network-based analysis was performed to identify candidate biomarkers. The candidate biomarkers were further analyzed for their potential use in prognosis and diagnosis.

The candidate biomarkers included three TFs and seven miRNAs. Among them, the roles of MYCN, hsa-miR-137, hsa-miR-421, and hsa-miR-2110 in NB tumor development and progression have been studied and proven. On the other hand, the rest of the predicted biomarkers in our study, such as SPI1, POU2F2, hsa-miR-1305, hsa-miR-1976, hsa-miR-940 and hsa-miR-760, could serve as potential biomarkers to halt NB tumorigenicity. In addition, their role in other tumor development and progression has been studied. Our regulatory network shows that they interact with some well-studied NB biomarkers, including MYCN, which support their under-studied implication in NB development.

In conclusion, analyzing cellular interactome to identify potential biomarkers is a promising approach that can contribute to optimizing efficient therapeutic regimens to target NB vulnerabilities. This study proposes a deeper understanding of MYCN interactome, providing candidate routes for targeted therapies in NB.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

Life Sciences > Biological Sciences > Biological Techniques > Computational and Systems Biology > Bioinformatics
Cancer Genetics and Genomics
Life Sciences > Biological Sciences > Cancer Biology > Cancer Genetics and Genomics

Related Collections

With collections, you can get published faster and increase your visibility.

Understanding Cancer Dynamics and Improving Treatment Strategies Using Mathematical and Computational Oncology

This Collection includes mathematical and computational modeling techniques developed to better understand cancer dynamics with the goal of improved treatments.

Publishing Model: Open Access

Deadline: Jan 31, 2024

Systems Immunology

This Collection looks at systems immunology tools, methods, concepts and techniques to uncover mechanisms underlying immunological cell-states and their disorders.

Publishing Model: Open Access

Deadline: Dec 30, 2023